The bureaucratic bloat in federal research funding is finally facing a long-overdue reckoning, especially for indirect ...

BioAge licensed azelaprag from Amgen in 2021. Thousand Oaks ... It is chasing after Vertex Pharma’s VX-548, which also targets NaV1.8 and last month showed efficacy in a pair of phase 3 trials ...

In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Three years after beginning construction in southwestern Wake County, the pharmaceutical company Amgen celebrated the completion of its $550 million manufacturing plant in the town of Holly ...

Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.